0001209191-17-056991.txt : 20171016
0001209191-17-056991.hdr.sgml : 20171016
20171016152433
ACCESSION NUMBER: 0001209191-17-056991
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20171016
FILED AS OF DATE: 20171016
DATE AS OF CHANGE: 20171016
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: SLATTERY JOSEPH P
CENTRAL INDEX KEY: 0001246530
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-19437
FILM NUMBER: 171138620
MAIL ADDRESS:
STREET 1: C/O SAFESTITCH MEDICAL, INC.
STREET 2: 635 DAVID DRIVE, SUITE 300
CITY: MORRISVILLE
STATE: NC
ZIP: 27560
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: TRANSENTERIX INC.
CENTRAL INDEX KEY: 0000876378
STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
IRS NUMBER: 112962080
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 635 DAVIS DRIVE
STREET 2: SUITE 300
CITY: MORRISVILLE
STATE: NC
ZIP: 27560
BUSINESS PHONE: 919-765-8400
MAIL ADDRESS:
STREET 1: 635 DAVIS DRIVE
STREET 2: SUITE 300
CITY: MORRISVILLE
STATE: NC
ZIP: 27560
FORMER COMPANY:
FORMER CONFORMED NAME: SafeStitch Medical, Inc.
DATE OF NAME CHANGE: 20080211
FORMER COMPANY:
FORMER CONFORMED NAME: CELLULAR TECHNICAL SERVICES CO INC
DATE OF NAME CHANGE: 19930328
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2017-10-16
0
0000876378
TRANSENTERIX INC.
TRXC
0001246530
SLATTERY JOSEPH P
C/O TRANSENTERIX, INC.
635 DAVIS DRIVE, SUITE 300
MORRISVILLE
NC
27560
0
1
0
0
EVP and CFO
Common Stock
2017-10-16
4
X
0
200000
1.00
A
644365
D
Common Stock
25000
I
By IRA
Series A Warrants
1.00
2017-10-16
4
X
0
200000
0.00
D
2017-05-03
2017-10-31
Common Stock
200000
0
D
On October 16, 2017, the reporting person exercised his Series A warrants to purchase 200,000 shares of common stock of TransEnterix, Inc. (the "Company"), par value $0.001 per share, for a purchase price of $1.00 per share.
The expiration date of the Series A warrant accelerated to the date that is 10 business days after the Company provides written notice to warrant holders of its receipt of FDA clearance for the Senhance System, as set forth in the warrant.
/s/ Joshua Weingard as attorney-in-fact for Joseph Slattery
2017-10-16